|
|
|
| Research progress on the treatment of peritoneal metastasis of gastric cancer |
| HAN Bohan LYU Huifang CHEN Xiaobing |
| Department of Gastroenterology, Affiliated Tumor Hospital of Zhengzhou University, He′nan Province, Zhengzhou 450000, China |
|
|
|
Abstract Peritoneal metastasis of gastric cancer has high incidence and short survival time, which is one of the main causes of death in advanced gastric cancer. In spite of several advances have been made in diagnosis and treatment, the prognosis of patients with peritoneal metastasis is still lower. Effective preventive measures are as important as treatment of peritoneal metastasis. Hyperthemic intraperitoneal perfusion chemotherapy, extensive intraoperative peritoneal lavage, early postoperative intraperitoneal chemotherapy and postoperative adjuvant chemotherapy can improve the prognosis of patients with peritoneal metastasis in high-risk groups. The systemic chemotherapy is the main treatment for peritoneal metastasis of gastric cancer, which can be combined with a variety of treatment methods, including intraperitoneal chemotherapy, targeted therapy and immunotherapy. In particular, the conversion therapy can significantly improve the prognosis of gastric cancer patients with peritoneal metastasis. However, the selection of the groups, the regimens and the timing of the conversion therapy are still the current focus and difficulty. This article summarizes the research status of treatment for peritoneal metastasis of gastric cancer in recent years, thus providing some references for the clinical practice.
|
|
|
|
|
|
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Mi DH，Li Z，Yang KH，et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy（IHIC）for gastric cancer：a systematic review and meta-analysis of randomised controlled trials [J]. Int J Hyperthermia，2013，29（2）：156-167.
[3] Masuda T，Kuramoto M，Shimada S，et al. The effect of extensive intraoperative peritoneal lavage therapy（EIPL）on stage Ⅲ B+C and cytology-positive gastric cancer patients [J]. Int J Clin Oncol，2016，21（2）：289-294.
[4] Guo J，Xu A，Sun X，et al. Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer：The SEIPLUS Randomized Clinical Trial [J]. JAMA Surg，2019， 154（7）：610-616.
[5] Lemoine L，Sugarbaker P，Van der SK. Drugs，doses，and durations of intraperitoneal chemotherapy：standardising HIPEC and EPIC for colorectal，appendiceal，gastric，ovarian peritoneal surface malignancies and peritoneal mesothelioma [J]. Int J Hyperthermia，2017，33（5）：582-592.
[6] Park SY，Choi GS，Park JS，et al. Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer：A Case-Control Study from a Single Center [J]. Ann Surg Oncol，2016，23（7）：2266-2273.
[7] Sasako M，Sakuramoto S，Katai H，et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer [J]. J Clin Oncol，2011，29（33）：4387-4393.
[8] Kanda M，Murotani K，Kobayashi D，et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage Ⅱ/Ⅲ gastric cancer：A propensity score matching analysis [J]. Surgery，2015，158（6）：1573-1580.
[9] Noh SH，Park SR，Yang HK，et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy（CLASSIC）：5-year follow-up of an open-label，randomised phase 3 trial [J]. Lancet Oncol，2014，15（12）：1389-1396.
[10] Kim IH，Park SS，Lee CM，et al. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection：A Retrospective，Multi-Center Observational Study [J]. Ann Surg Oncol，2018，25（5）：1176-1183.
[11] Gunji S，Obama K，Matsui M，et al. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin [J]. Surgery，2013，154（5）：991-999.
[12] Yamashita K，Tsunoda S，Gunji S，et al. Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules [J]. Surg Today，2019，49（9）：785-794.
[13] Macri A，Morabito F. The use of intraperitoneal chemotherapy for gastric malignancies [J]. Expert Rev Anticancer Ther，2019，19（10）：879-888.
[14] Grass F，Vuagniaux A，Teixeira-Farinha H，et al. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis [J]. Br J Surg，2017，104（6）：669-678.
[15] Hubner M，Teixeira Farinha H，Grass F，et al. Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chem-otherapy for Peritoneal Carcinomatosis：A Retrospective Cohort Study [J]. Gastroenterol Res Pract，2017，2017：6852749.
[16] Demtroder C，Solass W，Zieren J，et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis [J]. Colorectal Dis，2016， 18（4）：364-371.
[17] Wu P，Wang P，Ma B，et al. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer：a meta-analysis [J]. Cancer Manag Res，2018，10：4759-4771.
[18] Yang LP，Wang ZX，He MM，et al. A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients [J]. Cancer Manag Res，2019，11：3993-4003.
[19] Ji ZH，Peng KW，Yu Y，et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases [J]. Int J Hyperthermia，2017，33（5）：562-570.
[20] Solaini L，Ministrini S，Bencivenga M，et al. Conversion gastrectomy for stage Ⅳ unresectable gastric cancer：a GIRCG retrospective cohort study [J]. Gastric Cancer，2019，22（6）：1285-1293.
[21] Zhu Z. Clinical significance and efficacy of conversion surgery for patients with stage Ⅳ gastric cancer [J]. Zho-nghua Wei Chang Wai Ke Za Zhi，2018，21（10）：1087-1092.
[22] Li HK，Morokoshi Y，Nagatsu K，et al. Locoregional therapy with alpha-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice [J]. Cancer Sci，2017，108（8）：1648-1656.
[23] Kang YK，Boku N，Satoh T，et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to，or intolerant of，at least two previous chemotherapy regimens（ONO-4538-12，ATTRACTION-2）：a randomised，double-blind，placebo-controlled，phase 3 trial [J]. Lancet，2017，390（10111）：2461-2471.
[24] Fuchs CS，Doi T，Jang RW，et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer：Phase 2 Clinical KEYNOTE-059 Trial [J]. JAMA Oncol，2018，4（5）：e180013.
[25] Shitara K，Ozguroglu M，Bang YJ，et al. Pembrolizumab versus paclitaxel for previously treated，advanced gastric or gastro-oesophageal junction cancer（KEYNOTE-061）：a randomised，open-label，controlled，phase 3 trial [J]. Lancet，2018，392（10142）：123-133. |
|
|
|
